GSK-4074386
- Generic Name
- GSK-4074386
Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT03250832
- Locations
- 🇫🇷
GSK Investigational Site, Villejuif cedex, France
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Phase 1
Recruiting
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 447
- Registration Number
- NCT02817633
- Locations
- 🇨🇳
GSK Investigational Site, Tainan, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath